Ibrutinib for the treatment of Waldenström macroglobulinemia

References

• Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol 2003;30(2):110-15
   PubMed Web of Science ®Google Scholar
• Gertz MA. Waldenstrom macroglobulinemia: 2015 update on diagnosis, risk stratification, and management. Am J Hematol 2015;90(4):346-54
   PubMed Web of Science ®Google Scholar
• Kapoor P, Paludo J, Vallumsetla N, Greipp PR. Waldenstrom macroglobulinemia: What a hematologist needs to know. Blood Rev 2015
   PubMedGoogle Scholar
• Wang H, Chen Y, Li F, et al. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer 2012;118(15):3793-800
   PubMed Web of Science ®Google Scholar
• Sekhar J, Sanfilippo K, Zhang Q, et al. Waldenstrom macroglobulinemia: a Surveillance. Epidemiology, and End Results database review from 1988 to 2005. Leuk Lymphoma 2012;53(8):1625-6
   PubMed Web of Science ®Google Scholar
• Buske C, Leblond V, Dimopoulos M, et al. Waldenstrom’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):vi155-9
   PubMed Web of Science ®Google Scholar
• Treon SP, Cao Y, Xu L, et al. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood 2014;123(18):2791-6
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med 2012;367(9):826-33
   PubMed Web of Science ®Google Scholar
• Yang G, Zhou Y, Liu X, et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood 2013;122(7):1222-32
   PubMed Web of Science ®Google Scholar
• Hensel M, Brust J, Ploger C, et al. Excellent long-term survival of 170 patients with Waldenstrom’s macroglobulinemia treated in private oncology practices and a university hospital. Ann Hematol 2012;91(12):1923-8
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Olszewski AJ, Hunter ZR, et al. Incidence of secondary malignancies among patients with Waldenstrom macroglobulinemia: An analysis of the SEER database. Cancer 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Anderson KC, Alsina M, Bensinger W, et al. Waldenstrom’s macroglobulinemia/lymphoplasmacytic lymphoma. version 2.2013. J Natl Compr Canc Netw 2012;10(10):1211-19
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Olszewski AJ, Kanan S, et al. Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol 2015;169(1):81-9
   PubMed Web of Science ®Google Scholar
• Sahin I, Leblebjian H, Treon SP, Ghobrial IM. Waldenstrom macroglobulinemia: from biology to treatment. Expert Rev Hematoly 2014;7(1):157-68
   PubMed Web of Science ®Google Scholar
• Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom’s macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res 2007;13(11):3320-5
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom’s macroglobulinemia. Blood 2014;124(4):503-10
   PubMed Web of Science ®Google Scholar
• Siegel DS, Kaufman JL, Raje NS, et al. Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenström Macroglobulinemia (WM). Blood 2014;124:21
   Web of Science ®Google Scholar
• Ghobrial IM, Gertz M, Laplant B, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28(8):1408-14
   PubMed Web of Science ®Google Scholar
• Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008;112(12):4452-7
   PubMed Web of Science ®Google Scholar
• Treon SP, Soumerai JD, Branagan AR, et al. Lenalidomide and rituximab in Waldenstrom’s macroglobulinemia. Clin Cancer Res 2009;15(1):355-60
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Roccaro A, Hong F, et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom’s macroglobulinemia. Clin Cancer Res 2010;16(3):1033-41
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Moreau P, Harris B, et al. A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia. Clin Cancer Res 2012;18(18):5043-50
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, de Vos S, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370(11):1008-18
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Campigotto F, Murphy TJ, et al. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia. Blood 2013;121(8):1296-303
   PubMed Web of Science ®Google Scholar
• Treon SP, Hanzis C, Tripsas C, et al. Bendamustine therapy in patients with relapsed or refractory Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011;11(1):133-5
   PubMed Web of Science ®Google Scholar
• Buckley CR. Agammaglobulinemia, by Col. Ogden C. Bruton, MC, USA, Pediatrics, 1952;9:722-728. Pediatrics 1998;102(1 Pt 2)):213-15
   PubMed Web of Science ®Google Scholar
• Vetrie D, Vorechovsky I, Sideras P, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993;361(6409):226-33
   PubMed Web of Science ®Google Scholar
• Buggy JJ, Elias L. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol 2012;31(2):119-32
   PubMed Web of Science ®Google Scholar
• Stevenson FK, Krysov S, Davies AJ, et al. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011;118(16):4313-20
   PubMed Web of Science ®Google Scholar
• Wiestner A. Targeting B-cell receptor signaling for anticancer therapy: The Bruton’s tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol 2013;31(1):128-30
   PubMed Web of Science ®Google Scholar
• de Gorter DJ, Beuling EA, Kersseboom R, et al. Bruton’s tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity 2007;26(1):93-104
   PubMed Web of Science ®Google Scholar
• Gachard N, Parrens M, Soubeyran I, et al. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstrom macroglobulinemia/lymphoplasmacytic lymphomas. Leukemia 2013;27(1):183-9
   PubMed Web of Science ®Google Scholar
• Varettoni M, Arcaini L, Zibellini S, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms. Blood 2013;121(13):2522-8
   PubMed Web of Science ®Google Scholar
• Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011;470(7332):115-19
   PubMed Web of Science ®Google Scholar
• Avbelj M, Wolz OO, Fekonja O, et al. Activation of lymphoma-associated MyD88 mutations via allostery-induced TIR-domain oligomerization. Blood 2014;124(26):3896-904
   PubMed Web of Science ®Google Scholar
• Loiarro M, Gallo G, Fanto N, et al. Identification of critical residues of the MyD88 death domain involved in the recruitment of downstream kinases. J Biol Chem 2009;284(41):28093-103
   PubMed Web of Science ®Google Scholar
• Cameron F, Sanford M. Ibrutinib: first global approval. Drugs 2014;74(2):263-71
   PubMed Web of Science ®Google Scholar
• ImbruvicaTM (ibrutinib) capsules for oral use: US prescribing information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205552s000lbl.pdf
   Google Scholar
• Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010;107(29):13075-80
   PubMed Web of Science ®Google Scholar
• Temburni S, Barrientos JC, Kolitz JE, et al. Ibrutinib Inhibits Concomitant TLR and BCR- Driven Proliferation of Chronic Lymphocytic Leukemia Cells and Overrides the Supportive Survival-Promoting Effects of Microenvironmental Signals. Blood 2014;124:21
   Web of Science ®Google Scholar
• Sagiv-Barfi I, Kohrt H, Burckhardt L, et al. Ibrutinib Enhances the Anti-Tumor Immune Response Induced By Intratumoral Injection of a TLR9 Ligand. Blood 2014;124:21
   Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369(1):32-42
   PubMed Web of Science ®Google Scholar
• Smith DD, Goldstein L, Cheng M, et al. Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib. Ann Hematol 2015;94(2):249-56
   PubMed Web of Science ®Google Scholar
• Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood 2014;123(12):1810-17
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia. N Engl J Med 2015;372(15):1430-40
   PubMed Web of Science ®Google Scholar
• Vij R, Chang BY, Berdeja JG, et al. Early changes in cytokines, chemokines and indices of bone metabolism in a phase 2 study of the bruton tyrosine kinase (Btk) inhibitor, ibrutinib (PCI-32765) in patients with relapsed or relapsed/refractory multiple myeloma (MM). ASH Annual Meeting Abstracts 2012;120(21):4039
   Google Scholar
• Hunter ZR, Xu L, Yang G, et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 2014;123(11):1637-46
   PubMed Web of Science ®Google Scholar
• Cao Y, Hunter ZR, Liu X, et al. The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia. Leukemia 2015;29(1):169-76
   PubMed Web of Science ®Google Scholar
• Cao Y, Hunter ZR, Liu X, et al. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88L265P-directed survival signalling in Waldenström macroglobulinaemia cells. Br J Haematol 2015;168(5):701-7
   PubMed Web of Science ®Google Scholar
• Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014;370(24):2286-94
   PubMed Web of Science ®Google Scholar
• Balasubramanian S, Schaffer M, Deraedt W, et al. Mutational analysis of patients with primary resistance to single-agent ibrutinib in relapsed or refractory Mantle Cell Lymphoma (MCL). Blood 2014;124(21):78
   Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31(1):88-94
   PubMed Web of Science ®Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369(6):507-16
   PubMed Web of Science ®Google Scholar
• Marostica E, Sukbuntherng J, Loury D, et al. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. Cancer Chemother Pharmacol 2015;75(1):111-21
   PubMed Web of Science ®Google Scholar
• Hodge LS, Ziesmer SC, Yang ZZ, et al. Constitutive activation of STAT5A and STAT5B regulates IgM secretion in Waldenstrom’s macroglobulinemia. Blood 2014;123(7):1055-8
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014;371(3):213-23
   PubMed Web of Science ®Google Scholar
• Wilson WH, Gerecitano JF, Goy A, et al. The Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. ASH Annual Meeting Abstracts 2012;120(21):686
   Google Scholar
• Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011;43(9):830-7
   PubMed Web of Science ®Google Scholar
• Niemann CU, Wiestner A. B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol 2013;23(6):410-21
   PubMed Web of Science ®Google Scholar
• Poulain S, Roumier C, Galiegue-Zouitina S, et al. Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia. Am J Hematol 2013;88(11):948-54
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Sagiv-Barfi I, Rafiq S, et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood 2014;123(12):1957-60
   PubMed Web of Science ®Google Scholar
• Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2014;15(10):1090-9
   PubMed Web of Science ®Google Scholar
• Ysebaert L, Levade M, Cedric G, et al. Elucidation of Mild Bleeding Disorders Reported Under Ibrutinib (Imbruvica(R)) Therapy: Implications for Optimal Clinical Management. Blood 2014;124:21
   PubMed Web of Science ®Google Scholar
• McMullen JR, Boey EJ, Ooi JY, et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood 2014;124(25):3829-30
   PubMed Web of Science ®Google Scholar
• Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood 2015;125(13):2062-7
   PubMed Web of Science ®Google Scholar
• Pinilla-Ibarz J, Chavez JC. Life after ibrutinib? A new unmet need in CLL. Blood 2015;125(13):2013-14
   PubMed Web of Science ®Google Scholar
• Dangi-Garimella S. FDA grants accelerated approval for ibrutinib for CLL. Am J Manag Care 2014;20(5 Spec No):E10
   PubMedGoogle Scholar
• FDA expands approved use of Imbruvica for rare form of non-Hodgkin lymphoma. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm432123.htm
   Google Scholar
• Treon SP PM, Trispas C, Meid K, et al. Ibrutinib in previously treated patients with Waldenstrom’s Macroglobulinemia. International Workshop on Waldenstrom’s Macroglobulinemia-8; London: 2014
   Google Scholar
• Treon SP, Cao Y, Xu L, et al. A prospective multicenter study of the Bruton’s tyrosine kinase inhibitor ibrutinib in patients with relapsed or refractory Waldenstrom’s Macroglobulinemia. Proc Am Soc Hematol Blood 2013;122:251A
   Google Scholar
• IMBRUVICA® (ibrutinib) Now Approved in Europe for Treatment of Two Blood Cancers. Available from: http://www.prnewswire.com/news-releases/imbruvica-ibrutinib-now-approved-in-europe-for-treatment-of-two-blood-cancers-279550192.html
   Google Scholar
• Pharmacyclics Announces. Collaboration with the National Cancer Institute to Develop its Novel Btk Inhibitor, PCI-32765 in Hematologic Malignancies. Available from: http://www.prnewswire.com/news-releases/pharmacyclics-announces-collaboration-with-the-national-cancer-institute-to-develop-its-novel-btk-inhibitor-pci-32765-in-hematologic-malignancies-127401513.html
   Google Scholar
• Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765. Available from: http://www.prnewswire.com/news-releases/janssen-biotech-inc-announces-collaborative-development-and-worldwide-license-agreement-for-investigational-anti-cancer-drug-pci-32765-135272798.html
   Google Scholar
• Imbruvica pricing info. Available from: http://www.goodrx.com/imbruvica
   Google Scholar
• Shanafelt TD, Borah BJ, Finnes HD, et al. Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels. J Oncol Pract 2015;11(3):252-8
   PubMed Web of Science ®Google Scholar
• Herter S, Sagiv-Barfi I, Chester C, et al. Obinutuzumab (GA101) is less prone to antagonism of immune effector function by ibrutinib than rituximab in vitro and in vivo. Blood 2014;124:21
   Web of Science ®Google Scholar
• Sharman JP, Farber CM, Mahadevan D, et al. Ublituximab (TG-1101), a novel glycoengineered Anti-CD20 monoclonal antibody, in combination with ibrutinib is highly active in patients with relapsed and/or refractory CLL and MCL; results of a phase II Trial. Blood 2014;124:21
   Web of Science ®Google Scholar
• Martin P, Maddocks KJ, Noto K, et al. Poor overall survival of patients with ibrutinib-resistant mantle cell lymphoma. Blood 2014;124:21
   Google Scholar
• Kuo H-P, Crowley R, Xue L, et al. Combination of ibrutinib and BCL-2 or SYK inhibitors in ibrutinib resistant ABC-subtype of diffuse large B-cell lymphoma. Blood 2014;124:21
   Web of Science ®Google Scholar
• Portell CA, Axelrod M, Brett LK, et al. Synergistic cytotoxicity of ibrutinib and the BCL2 antagonist, ABT-199(GDC-0199) in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL): molecular analysis reveals mechanisms of target interactions. Blood 2014;124:21
   Web of Science ®Google Scholar
• Chitta KS, Paulus A, Blake-Kuranz M, et al. The selective Bcl-2 inhibitor ABT-199 synergizes with BTK or proteasome inhibitors to induce potent cell death in preclinical models of bortezomib or ibrutinib-resistant Waldenströms macroglobulinemia. Blood 2014;124:21
   Web of Science ®Google Scholar
• Vakkalanka S, Nyayapathy S, Viswanadha S. Addition of RP6530, a dual PI3Kδ/γ inhibitor, overcomes ibrutinib resistance in DLBCL cells in vitro. Blood 2014;124:21
   Web of Science ®Google Scholar
• Ngo HT, Leleu X, Lee J, et al. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood 2008;112(1):150-8
   PubMed Web of Science ®Google Scholar
• Cao Y, Yang G, Hunter ZR, et al. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 and CXCR4 mutated Waldenstrom macroglobulinaemia cells. Br J Haematol 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• McDermott DH, Liu Q, Velez D, et al. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood 2014;123(15):2308-16
   PubMed Web of Science ®Google Scholar
• Cao Y, Yang G, Hunter ZR, et al. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4Wild-type and CXCR4WHIM mutated Waldenstrom macroglobulinaemia cells. Br J Haematol 2015; 10.1111/bjh.13278. [Epub ahead of print]
   Google Scholar
• Cagnetta A CM, Fulciniti M, Yu-Tzu T, et al. Inhibition of NAMPT augments ibrutinib induced killing in MYD88 L265P expressing Waldenstrom’s Macroglobulinemia cells. Haematologica 2014;99:S1
   Google Scholar
• Burger JA. Bruton’s tyrosine kinase (BTK) inhibitors in clinical trials. Curr Haematol Malig Rep 2014;9(1):44-9
   PubMed Web of Science ®Google Scholar